The Ki67 tumor expression yielded significant survival advantages within the group with low Ki67 expression (31.2 vs. 11.1 months, p = 0.012; Figure 1b and Table 2), suggesting that indeed high Ki67 expression is associated with a more aggressive biological subtype of malignant disease, resulting in poor patient survival. Here, MKI67 is linked to neoplasm.